Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Omeros Corporation (OMER)
:OMER
Holding OMER?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.69Last Year’s EPS
-0.15Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: 122.67%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development programs, cost reductions, and regulatory advancements, particularly for narsoplimab and zaltenibart. However, financial challenges remain with decreased cash reserves and declining OMIDRIA sales. Despite these challenges, the sentiment leans positive due to strategic advancements and potential new revenue streams.Company Guidance
During the Omeros Corporation earnings call for Q3 2024, detailed guidance was provided on several fronts. The company reported a net loss of $32.2 million or $0.56 per share, a significant improvement from the previous quarter's $56 million or $0.97 per share. Cash and investments stood at $123.2 million as of September 30, 2024, a decrease from $159 million at the end of Q2. The decrease in net loss was primarily attributed to reduced R&D expenses, including a $17.6 million expense for narsoplimab drug substance in the previous quarter. Upcoming strategies include leveraging the expanded payment for OMIDRIA in hospital outpatient departments starting January 2025, expected to significantly boost U.S. sales. Additionally, Omeros is preparing to resubmit its Biologics License Application for narsoplimab, with possible commercialization in 2025, and is advancing its Phase III trials for zaltenibart in treating paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also exploring further international market entries and potential additional indications for its drug candidates.Reduced Net Loss
The net loss for Q3 2024 was $32.2 million or $0.56 per share, a significant improvement from the $56 million or $0.97 per share in Q2 2024.
Progress in Drug Development Programs
Ongoing development and Phase III program initiation for zaltenibart (OMS906), targeting PNH and C3G, with positive efficacy and safety data.
Regulatory Milestones
FDA pre-submission meeting for narsoplimab BLA resubmission was collaborative, with minor additional feedback requested. European marketing authorization application (MAA) for narsoplimab expected in H1 2025.
Rare Pediatric Disease Designation
zaltenibart received FDA rare pediatric disease designation for C3 glomerulopathy, potentially leading to a priority review voucher.
OMIDRIA Revenue Prospects
Expansion of separate payment for OMIDRIA in hospital outpatient departments starting January 2025, expected to grow sales significantly in the U.S.
---
OMER Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OMER Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $4.19 | $6.95 | +65.87% |
| Aug 07, 2024 | $4.15 | $3.91 | -5.78% |
| May 15, 2024 | $4.17 | $3.31 | -20.62% |
| Apr 01, 2024 | $3.19 | $3.05 | -4.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Omeros Corporation (OMER) report earnings?
Omeros Corporation (OMER) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Omeros Corporation (OMER) earnings time?
Omeros Corporation (OMER) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OMER EPS forecast?
OMER EPS forecast for the fiscal quarter 2024 (Q4) is -0.69.
---